Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders
Accessibility StatementSkip Navigation Also from this source MILWAUKEE, Nov. 4, 2025 /PRNewswire/ -- The Ademi Firm is investigating Evoke (NASDAQ: EVOK) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Evoke shareholders will receive $11.00 per ...